| Literature DB >> 33908239 |
Yekaterina Lebedeva1, Laura Churchill1, Jacquelyn Marsh1, Steven J MacDonald1, J Robert Giffin1, Dianne Bryant1.
Abstract
Background: The escalating socioeconomic burden of knee osteoarthritis (OA) underscores the need for innovative strategies to reduce wait times for total knee arthroplasty (TKA). The purpose of this study was to evaluate resource use, costs and health-related quality of life (HRQoL) across the continuum of care for patients with knee OA.Entities:
Year: 2021 PMID: 33908239 PMCID: PMC8327991 DOI: 10.1503/cjs.003419
Source DB: PubMed Journal: Can J Surg ISSN: 0008-428X Impact factor: 2.089
Fig. 1Study flow. HRQoL = health-related quality of life; TKA = total knee arthroplasty. *The new consults group consisted of 189 new consults and 43 new referrals. †The presurgical group consisted of 119 presurgical patients and 32 new consults who had undergone surgery at the time of data analysis.
Demographic characteristics of study participants
| Characteristic | No. (%) of patients; | ||
|---|---|---|---|
| New referrals | New consults | Presurgical | |
| Age, yr, mean ± SD | 68.3 ± 9.3 | 66.0 ± 9.5 | 66.8 ± 8.9 |
| Sex, female | 31 (53.4) | 116 (60.4) | 68 (56.7) |
| Body mass index, kg/m2, mean ± SD | 31.4 ± 7.9 | 32.0 ± 8.3 | 34.9 ± 7.9 |
| Dominant side, right | 51 (87.9) | 171 (89.1) | 114 (95.0) |
| Affected knee, right | 25 (43.1) | 103 (53.6) | 60 (50.0) |
| Contralateral symptoms | 41 (70.7) | 157 (81.8) | 80 (66.7) |
| Previous joint arthroplasty | 6 (10.3) | 19 (9.9) | 40 (33.3) |
| Global rating of knee pain (0–10), mean ± SD | 6.6 ± 2.3 | 5.4 ± 2.4 | 5.3 ± 2.2 |
| PASS 2, yes | 23 (39.7) | 96 (50.0) | N/A |
| Living arrangements | |||
| Alone | 12 (20.7) | 52 (27.1) | 25 (20.8) |
| With spouse or partner | 42 (72.4) | 108 (56.3) | 78 (65.0) |
| With other family member(s) | 3 (5.2) | 32 (16.8) | 17 (14.2) |
| Residential care facility | 1 (1.7) | 0 | 0 |
| Stairs at home, yes | 49 (84.5) | 137 (71.6) | 70 (58.3) |
| Employment status | |||
| Retired | 32 (55.2) | 105 (55.3) | 75 (63.0) |
| Full time | 11 (19.0) | 49 (25.8) | 17 (14.2) |
| Part time | 6 (10.3) | 12 (6.3) | 12 (10.0) |
| Self-employed | 2 (3.4) | 2 (1.1) | 4 (3.4) |
| Volunteer | 1 (1.7) | 2 (1.1) | 1 (0.8) |
| Long-term disability | 0 | 8 (4.2) | 4 (3.3) |
| Temporary sick leave | 0 | 5 (2.6) | 4 (3.3) |
| Unemployed | 0 | 3 (1.6) | 0 |
| Other | 0 | 4 (2.1) | 2 (1.7) |
| Annual household income | |||
| < $20 000 | 5 (8.6) | 29 (15.3) | 12 (10.0) |
| $20 000–$40 000 | 13 (22.4) | 49 (25.8) | 24 (20.8) |
| $40 000–$60 000 | 7 (12.1) | 29 (15.3) | 24 (20.0) |
| $60 000–$80 000 | 12 (20.7) | 26 (13.7) | 16 (13.3) |
| $80 000–$100 000 | 3 (5.2) | 18 (9.5) | 24 (20.0) |
| > $100 000 | 11 (19.0) | 31 (16.2) | 14 (11.7) |
| Undisclosed | 2 (3.4) | 8 (4.2) | 5 (4.2) |
PASS 2 = patient acceptable symptom state; SD = standard deviation.
Unless indicated otherwise.
Data available for 52 new referrals and 190 new consults.
Data available for 53 new referrals and 190 new consults.
Patient-reported use of nonoperative treatments at different stages of care
| Nonoperative treatment | No. (%) of patients; | ||
|---|---|---|---|
| Prereferral | Presurgery | Long-term follow-up | |
| Physiotherapy | 123 (49.6) | 40 (33.6) | 7 (50.0) |
| Recommended but opted out | 11 (4.4) | 1 (0.8) | 0 |
| Chiropractic therapy | 17 (6.9) | 6 (5.0) | 1 (7.1) |
| Recommended but opted out | 1 (0.4) | 0 | 0 |
| Occupational therapy | 7 (2.8) | 4 (3.4) | 1 (7.1) |
| Recommended but opted out | 0 | 0 | 0 |
| Massage therapy | 33 (13.3) | 9 (7.6) | 2 (16.0) |
| Osteopathy | 8 (3.2) | 1 (0.8) | 1 (7.1) |
| Acupuncture | 18 (7.3) | 7 (5.9) | 0 (4.0) |
| Pedorthist or orthotist services | 57 (23.0) | 14 (11.8) | 1 (7.1) |
| Intra-articular joint injections | 142 (57.3) | 33 (27.7) | 2 (14.3) |
| Corticosteroid | 122 (49.2) | 29 (24.4) | 1 (7.1) |
| Hyaluronic acid | 37 (14.9) | 1 (0.8) | 0 |
| Unknown | 10 (4.0) | 2 (1.7) | 1 (7.1) |
| Other | 2 (0.8) | 0 | 0 |
| Recommended but opted out | 12 (4.8) | 1 (0.8) | 1 (7.1) |
| Weight loss | 53 (21.4) | 34 (28.6) | 5 (35.7) |
| No. of kg lost, mean ± SD | 9.1 ± 9.7 | 6.1 ± 5.9 | 7.2 ± 6.4 |
| Exercise | 176 (71.0) | 92 (77.3) | 8 (57.1) |
| Aerobic | 128 (51.6) | 75 (63.0) | 5 (35.7) |
| Resistance | 88 (35.5) | 39 (32.8) | 4 (28.6) |
| Stretching | 116 (46.8) | 67 (56.3) | 3 (21.4) |
| Other | 4 (1.6) | 0 | 2 (14.3) |
| Activity modification | 201 (81.0) | 93 (72.8) | 7 (50.0) |
| Gait aid | 92 (37.1) | 52 (43.7) | 5 (35.7) |
| Topical NSAID | 183 (73.8) | 70 (58.8) | 4 (28.6) |
| Knee sleeve or brace | 105 (42.3) | 42 (35.3) | 4 (28.6) |
| Specialized footwear | 76 (30.6) | 32 (26.9) | 4 (28.6) |
| Oral medications | 209 (84.3) | 107 (89.9) | 7 (50.0) |
| NSAIDs | 143 (57.7) | 79 (66.4) | 4 (28.6) |
| Analgesics | 169 (68.1) | 70 (58.8) | 2 (14.3) |
| Steroids | 6 (2.4) | 8 (6.7) | 1 (7.1) |
| Antirheumatoid agents | 5 (2.0) | 3 (2.5) | 0 |
| Other | 22 (8.9) | 24 (20.2) | 0 |
NSAID = nonsteroidal anti-inflammatory drug; SD = standard deviation.
Unless indicated otherwise.
Costs over the continuum of care by payer perspective
| Stage of care | Health care payer perspective | Patient and private insurer perspective | Societal perspective | |||||
|---|---|---|---|---|---|---|---|---|
|
|
|
| ||||||
| Cost, $CAD | % of total cost | Cost, $CAD | % of total cost | Total cost, $CAD | ||||
|
|
|
| ||||||
| Mean ± SD | Median (IQR) | Mean ± SD | Median (IQR) | Mean ± SD | Median (IQR) | |||
| Initial consult ( | 116.48 ± 184.04 | 76.48 (118.78) | 6.8 | 1598.39 ± 3675.87 | 242.57 (1113.86) | 93.2 | 1714.87 ± 2910.44 | 414.30 (1128.96) |
|
| ||||||||
| 3 mo after consult ( | 105.00 ± 198.91 | 42.60 (154.40) | 3.8 | 2635.97 ± 6677.55 | 279.51 (1535.87) | 96.2 | 2740.98 ± 6684.52 | 417.80 (1615.65) |
|
| ||||||||
| 6 mo after consult ( | 103.86 ± 203.66 | 36.03 (154.40) | 4.2 | 2318.86 ± 4642.18 | 431.00 (1891.03) | 95.8 | 2422.73 ± 4677.75 | 505.45 (2130.84) |
|
| ||||||||
| 9 mo after consult ( | 65.41 ± 98.56 | 33.30 (83.39) | 2.6 | 2589.05 ± 5513.81 | 485.82 (2024.21) | 97.4 | 2615.69 ± 5484.18 | 515.13 (2045.97) |
|
| ||||||||
| 12 mo after consult ( | 841.09 ± 2226.33 | 64.58 (142.14) | 15.0 | 4735.09 ± 10454.90 | 499.39 (3765.48) | 85.0 | 5576.17 ± 10 785.96 | 562.53 (5153.33) |
|
| ||||||||
| Presurgery ( | 299.58 ± 82.35 | 262.45 (80.83) | 12.6 | 2085.37 ± 5033.54 | 122.54 (838.32) | 87.4 | 2384.94 ± 5055.13 | 461.39 (864.55) |
|
| ||||||||
| 1.5 mo after surgery ( | 7346.24 ± 288.71 | 7269.91 (81.60) | 50.1 | 7310.24 ± 8879.38 | 12 453.66 (8528.38) | 49.9 | 14656.48 ± 8838.40 | 12 453.66 (8528.38) |
|
| ||||||||
| 6 mo after surgery ( | 208.42 ± 957.91 | 64.80 (129.98) | 15.5 | 1146.92 ± 3254.51 | 59.31 (506.79) | 84.5 | 1355.35 ± 3598.62 | 219.42 (592.28) |
|
| ||||||||
| 9 mo after surgery ( | 244.74 ± 1154.54 | 24.05 (94.16) | 15.4 | 1603.61 ± 4691.87 | 195.31 (614.00) | 84.6 | 1848.35 ± 4819.13 | 241.70 (896.86) |
|
| ||||||||
| 12 mo after surgery ( | 138.52 ± 328.40 | 45.87 (123.41) | 5.1 | 2579.53 ± 4446.37 | 143.31 (2573.62 | 94.9 | 2718.05 ± 4646.69 | 244.79 (2743.32) |
|
| ||||||||
| Long-term follow-up (no surgery) ( | 816.58 ± 2699.44 | 78.00 (176.76) | 10.6 | 1228.30 ± 2371.09 | 176.47 (1657.89) | 89.4 | 2044.88 ± 3414.59 | 370.59 (1938.54) |
IQR = interquartile range; SD = standard deviation.
Fig. 2Distribution of direct and indirect costs of knee osteoarthritis incurred by new referrals at their initial surgical consultation.
Fig. 3Distribution of direct and indirect costs of knee osteoarthritis at the preadmission appointment before patients underwent total knee arthroplasty. Patients recalled costs over the last 3 months.
Fig. 4Distribution of direct and indirect costs of knee osteoarthritis at the long-term follow-up. Patients in this group were deemed unsuitable candidates for total knee arthroplasty at their first consultation and had not pursued surgical treatment since. Patients recalled costs over the last 3 months.
Health-related quality of life across different stages of care
| Measure (range of possible values) | Score, mean ± SD; stage of care | ||||
|---|---|---|---|---|---|
| Referral | Consultation | Presurgery | 12 mo after surgery | Long-term | |
| EQ-5D index (0–1) | 0.78 ± 0.15 | 0.78 ± 0.11 | 0.79 ± 0.10 | 0.84 ± 0.11 | 0.85 ± 0.08 |
| EQ-5D VAS (0–100) | 65.9 ± 19.1 | 61.8 ± 18.9 | 64.2 ± 18.7 | 74.49 ± 19.14 | 79.2 ± 11.0 |
| SF-12 PCS (0–100) | 30.5 ± 8.2 | 30.5 ± 8.0 | 31.2 ± 8.1 | 42.0 ± 10.5 | 41.7 ± 8.9 |
| SF-12 MCS (0–100) | 52.8 ± 10.9 | 49.9 ± 12.2 | 52.4 ± 10.3 | 51.4 ± 11.4 | 51.6 ± 8.5 |
| WOMAC pain (0–20) | 9.2 ± 3.6 | 9.7 ± 3.6 | 10.5 ± 3.8 | 15.3 ± 4.7 | 14.8 ± 4.8 |
| WOMAC stiffness (0–8) | 3.9 ± 1.9 | 3.5 ± 1.7 | 3.8 ± 1.7 | 5.5 ± 3.1 | 5.2 ± 2.4 |
| WOMAC function (0–68) | 33.1 ± 12.5 | 33.1 ± 12.6 | 32.4 ± 11.8 | 52.3 ± 14.4 | 50.7 ± 15.4 |
| Total WOMAC (0–96) | 49.8 ± 16.5 | 49.7 ± 16.8 | 49.1± 15.4 | 22.8 ± 20.5 | 25.2 ± 22.2 |
Note: Higher scores indicate better outcomes. EQ-5D = EuroQoL 5-Dimension 5-Level too; IQR = interquartile range; MCS = mental component score; PCS = physical component score; SD = standard deviation; SF-12 = 12-Item Short Form Health Survey (version2); VAS = visual analogue scale; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index.
Patients in this group had not undergone surgery since their initial consultation.
Fig. 5Conceptual model of our proposed online platform intended to offer a cost-effective solution to improve the quality of care for patients with osteoarthritis of the knee. PCP = primary care provider; WT1 = wait time from referral to initial surgical consulation.